(NASDAQ: ENTA) Enanta Pharmaceuticals's forecast annual revenue growth rate of -6.05% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 30.84%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.9%.
Enanta Pharmaceuticals's revenue in 2026 is $65,258,000.On average, 7 Wall Street analysts forecast ENTA's revenue for 2026 to be $1,909,519,606, with the lowest ENTA revenue forecast at $1,821,881,271, and the highest ENTA revenue forecast at $1,987,808,687. On average, 7 Wall Street analysts forecast ENTA's revenue for 2027 to be $1,715,049,297, with the lowest ENTA revenue forecast at $1,518,190,705, and the highest ENTA revenue forecast at $1,957,227,014.
In 2028, ENTA is forecast to generate $1,589,373,187 in revenue, with the lowest revenue forecast at $1,427,144,698 and the highest revenue forecast at $1,743,155,310.